anti-Cytokine Receptor-Like Factor 2 (CRLF2) Antibodies

Human Cytokine Receptor-Like Factor 2 (CRLF2) interaction partners

1. CRLF2 overexpression was observed in 14% (PHOP) and 16% (TARGET) of T-ALL patients. CRLF2 expression associates with stabilization of the intracellular domain of NOTCH1.

2. Study results demonstrated that CRLF2 overexpression is associated with a poor prognosis in Bcell acute lymphoblastic leukemia (BALL), and the CRLF2/AKT/mTOR pathway is involved in the migration, invasion and chemotherapeutic agentinduced apoptosis of BALL cells.

3. expression of CRLF2 was significantly increased in basophils of patients with allergic rhinitis after allergen stimulation

4. Family-based whole genome analysis of a family with hereditary pulmonary alveolar proteinosis revealed a homozygous deletion that disrupts CSF2RA, CRLF2, and IL3RA gene in the pseudoautosomal region of the X chromosome in the affected child and one of asymptomatic siblings.

5. TSLP expression on the basophil membrane of patients with severe asthma was not significantly different from healthy controls.

6. high CRLF2 expression works with the IKZF1 deletion to drive oncogenesis of acute lymphoblastic leukemia

7. this study shows that CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia

8. data suggest that this high frequency of genetic aberrations in the context of a high CRLF2 expression could contribute to the high risk of relapse in P2RY8/CRLF2- and IGH/CRLF2-positive acute lymphoblastic leukemia.

9. CRLF2 overexpression is associated with childhood B-cell acute lymphoblastic leukemia.

10. CRLF2 gene rearrangement is associated with acute lymphoblastic leukemia.

11. TSLPR levels were found to be significantly higher in asthmatic than in nonasthmatic children. TSLPR expression in non-allergic asthmatic and allergic asthmatic groups was found to be significantly higher than in non-allergic nonasthmatic group

12. In adult B-cell acute lymphoblastic leukemia without recurrent fusion genes , high CRLF2 expression is associated with distinct clinico-biological features and an unfavourable prognosis

13. CD4+ T cells from atopic dermatitis patients directly interacted with TSLP to produce a higher amount of IL-4 than those from normal subjects, and this action was attenuated with anti-TSLPR antibody

14. The levels of mRNA for TSLP and TSLPR were significantly elevated in parotid gland tissues from the KD group as compared to the control group.

15. Differences exist in the genetic profiles of Down syndrome-associated acute lymphoblastic leukemia patients in Japan and in Western countries, and that P2RY8-CRLF2 and EBF1 deletions may cooperate in leukemogenesis in a subset of Japanese DS-ALL patients.

16. CRLF2 overexpression (OE) was detected in 30 (18%) of 167 patients, the P2RY8-CRLF2 fusion was identified in only 3 (1.8%) of 167 patients, all of which demonstrated CRLF2 OE.

17. we report noncysteine in-frame mutations in IL7R and CRLF2 located in a region of the transmembrane domain closer to the cytosolic domain in acute lymphoblastic leukemias

18. The TSLPR in blood plateltes promotes platelet activation via activating the PI3K/AKT pathway.

19. both IKZF1 deletions and IGH@-CRLF2 are associated with an increased risk of treatment failure in adult acute lymphoblastic leukemia

20. Data indicate that CD66c is frequently expressed in CRLF2-positive as well as hypodiploid cases.

Mouse (Murine) Cytokine Receptor-Like Factor 2 (CRLF2) interaction partners

1. these results suggest that TSLP-TSLPR signaling is pivotal in the induction of nasal respiratory immunity against pathogenic pneumococcal infection

2. A novel mouse xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis has been developed.

3. High-cholesterol diet increased TSLPR expression and atherosclerosis. High-dose ticagrelor moderated this trend. It modulated platelet activity and atherosclerosis mediated by TSLPR, potentially through the PI3K/Akt signal pathway.

4. Activating thymic stromal lymphopoietin promotes atherosclerosis by inducing Th17/Treg imbalance through TSLPR signaling in a mouse model.

5. Suggest that Treg defects in ApoE(-/-) mice might partially be attributed to the disruption of TSLP-TSLPR-LAP signaling in epithelial cells and dendritic cells.

6. The structure of the mouse TSLP-mediated signaling complex reveals how TSLP establishes extensive interfaces with its cognate receptor (TSLPR).

7. TSLPR helps to create a permissive microenvironment for the development and pulmonary metastasis of mammary carcinoma in a mouse model using implanted 4T1 tumour cells.

8. A previously unrecognized role was found for TSLP/TSLPR signaling in type 2 immunity as an important enhancer for the development of alternately activated macrophages as well as for chemokine production.

9. mice deficient in TSLP receptors on LCs abrogated the induction of OVA-specific IgE levels upon epicutaneous OVA sensitization.

10. Increased susceptibility to autoimmune gastritis in thymic stromal lymphopoietin receptor-deficient mice.

11. Presence of functional TSLP-specific receptor chain is required for the development of T helper cell type (Th)2 contact hypersensitivity to the hapten fluorescein isothiocyanate (FITC).

12. Induced homodimerization of receptor chimeras containing the transmembrane and cytoplasmic domains of both human and mouse TSLP receptors is not sufficient for driving cell proliferation.

13. expression pattern in antigen presenting cells

14. B-cell development, including the IgM+ compartment, was unaffected by loss of the TSLPR pathway.

15. molecular cloning of Tslpr in insect cells or COS cells resulted in expression of mTSLPR with an extracellular C-terminal end, a surprising result since the N-terminal region contains a signal sequence and two potential glycosylation sites

16. local application of anti-TSLPR prevented Th2-mediated airway inflammation, at least partly, by regulating DCs function, which might be exploited to develop novel treatments for asthma.